Last C$0.11 CAD
Change Today 0.00 / 0.00%
Volume 1.0M
SBM On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 3:59 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

sirona biochem corp (SBM) Snapshot

Open
C$0.11
Previous Close
C$0.11
Day High
C$0.12
Day Low
C$0.11
52 Week High
09/30/13 - C$0.21
52 Week Low
07/18/14 - C$0.09
Market Cap
12.8M
Average Volume 10 Days
348.5K
EPS TTM
C$-0.05
Shares Outstanding
121.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SIRONA BIOCHEM CORP (SBM)

Related News

No related news articles were found.

sirona biochem corp (SBM) Related Businessweek News

No Related Businessweek News Found

sirona biochem corp (SBM) Details

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada. The company develops programs in three areas, including diabetes and cancer therapeutics; anti-aging and depigmenting agent in cosmeceuticals; biological ingredients, such as inducers and adjuvants for biological development. It develops a sodium glucose co-transporter inhibitor for the treatment of Type 2 diabetes; and a cancer vaccine antigen. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Founded in 2006

sirona biochem corp (SBM) Top Compensated Officers

Founder, Chairman of the Board, Interim Chief...
Total Annual Compensation: C$95.0K
Chief Financial Officer and Director
Total Annual Compensation: C$102.0K
Compensation as of Fiscal Year 2013.

sirona biochem corp (SBM) Key Developments

Sirona Biochem Announces Successful Completion of Two First Line Studies by Wanbang Biopharmaceuticals

Sirona Biochem Corp. announced that Wanbang Biopharmaceuticals has completed two pre-clinical efficacy studies of its SGLT2 inhibitor SBM-TFC-039. The studies independently confirm that SBM-TFC-039 increased Urinary Glucose Excretion and improved Oral Glucose Tolerance in normal SD rats. The results were consistent with those previously completed by Sirona Biochem. The next steps in the validation of SBM-TFC-039 will be the Pharmacokinetic study and the 14 day toxicology repeated administration on normal SD rats. If further positive results are obtained, as expected, Wanbang will have completed the first milestone of its license agreement with Sirona Biochem. This will trigger a second payment to Sirona from Wanbang Biopharmaceuticals, part of the $9.5M in upfront and milestone payments.

Sirona Biochem Corp. Announces Management Changes

Sirona Biochem Corp. announced that Neil Belenkie has resigned as Chief Executive Officer of the company. Neil has agreed to stay on with the company to assist in the transition until July 18, 2014. Dr. Howard Verrico has been appointed interim CEO by the board of directors.

Sirona Biochem Corp. Adopts New Articles of Association

Sirona Biochem Corp. announced at its Annual General and Special Meeting held on June 10, 2014 has approved the adoption of new articles of the company. The new articles will bring the company up to date with current corporate practices, including incorporating advance notice provisions with respect to election of directors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBM:CN C$0.11 CAD 0.00

SBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBM.
View Industry Companies
 

Industry Analysis

SBM

Industry Average

Valuation SBM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 47.7x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIRONA BIOCHEM CORP, please visit www.sironabiochem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.